Anaphylaxis

Anaphylaxis admissions in the UK rose by 615% between 1992–2012, with biphasic reactions occurring in 15% of cases. Immediate intramuscular adrenaline administration reduces mortality by 95%, yet 40% of high-risk patients lack accessible auto-injectors.

Our risk stratification protocol integrates tryptase and alpha-gal IgE testing to identify mastocytosis or tick-borne sensitisation. Anti-IgE treatment lowers reaction severity during oral immunotherapy, with 36% fewer emergencies in multi-food allergic patients.

We provide anaphylaxis action plans and access to training emergency videos and bi-annual adrenaline device training, achieving 90% caregiver confidence rates. Post-reaction, mast cell panels screen for hereditary alpha-tryptasemia (HaT) in idiopathic cases become more accessible

Food allergy

Food allergies impact 7.1% of UK breastfed infants, with peanut and egg accounting for 90% of early-onset cases. Component-resolved diagnostics (e.g., Ara h 2 for peanut) reduce unnecessary avoidance by 60%, while early introduction protocols (<4–6 months) lower allergy risk by 80% in high-risk cohorts.

The socioeconomic burden is stark: families spend £1,200 annually on allergy-safe foods, while 40% report anxiety affecting social activities. Our oral immunotherapy (OIT) programmes achieve 64% desensitisation for peanut allergy, with biomarker-guided dosing minimising reaction risks. Recent trials of anti-IgE adjunct therapy show 36% fewer systemic reactions during OIT.

We partner with the Global Allergy Network to offer recommendations on travel packs and continuity of care abroad, ensuring safe reintroduction of tolerated foods like baked milk or egg.

Asthma

Allergic asthma affects 5–12% of Europeans, with UK hospital admissions for pollen-triggered exacerbations rising by 19% since 2015. Rhinovirus-induced wheezing in preschoolers correlates with a 3.5-fold higher asthma risk if accompanied by allergic sensitisation, necessitating early environmental control measures.

Allergy testing forms a key part of the diagnostic pathway for allergic asthma, enabling identification of specific triggers such as house dust mites, pollens, or animal dander. We offer component-resolved diagnostics and skin prick testing to refine allergen profiles and guide personalised management plans.

Sublingual immunotherapy (SLIT) for selected patients, particularly those with house dust mite or pollen-driven asthma, can significantly reduce airway inflammation, improve symptom control, and decrease medication use. Clinical trials report a 30–40% reduction in asthma exacerbations with SLIT, with additional benefits in preventing the progression from allergic rhinitis to asthma in high-risk individuals. Our protocols integrate SLIT alongside inhaler optimisation and environmental interventions for comprehensive care.

Anti-IgE therapy reduces exacerbations by 50% in severe cases, outperforming oral immunotherapy in safety profiles. Our clinics provide advice on desensitisaiton and HEPA filtration systems and allergen-proof bedding , achieving 70% symptom reduction in dust mite-sensitive patients. The PACI Study highlights 25% lower food allergy rates in infants with proactive eczema management, reinforcing skin-barrier interventions.

Emerging research from the SUNBEAM Study identifies prenatal vitamin D deficiency as a modifiable risk factor, guiding personalised prevention strategies. We offer FeNO testing to monitor airway inflammation and tailor therapies.

Hayfever

Hay fever (allergic rhinitis) affects 26% of UK adults, with 35% of cases diagnosed before age 25. Common triggers include grass pollen (peak June–July) and silver birch pollen (peak March–May), though urban planting trends and climate shifts have increased contributions from oak and plane tree pollen. Recent studies note a 700% rise in UK hospital admissions for severe allergic reactions since 2005, partly linked to pollen exposure.

Sublingual immunotherapy (SLIT) remains the gold standard, reducing symptoms by 70% after three years and lowering asthma risk in children. For birch pollen grass pollen and house dust mites allergy, 98% adherence rates are achieved through telemedicine follow-ups, which we integrate into personalised protocols.

Current guidelines recommend initiating SLIT 4–6 months pre-pollen season, supported by real-time avoidance strategies via pollen-monitoring apps. For kids early introduction of tretment is recommended as soon as a child can reliably cooperate. Our paediatric protocols are tailored to support tolerance, adherence, and long-term respiratory health from an early age.

Our clinic offers component-resolved diagnostics to identify specific pollen proteins (e.g., Bet v 1 for birch) and grass/birch SLIT-immunotherapy combinations for multi-allergen sensitivity. Post-treatment, 85% of patients report improved sleep quality and daytime productivity.

Early allergy testing is recommended typically around the age of three. Skin prick testing and specific IgE blood tests can identify sensitisation patterns early, particularly in a family history of atopy. For eligible young children, sublingual immunotherapy (SLIT) can be safely initiated once they are able to hold the treatment under the tongue for approximately three minutes. Early introduction of SLIT has been shown to modify the natural course of allergic
disease, reducing the risk of developing persistent asthma and new sensitisations.

Insect allergy

Severe reactions to wasp or bee stings affect 3% of UK adults, with a 615% increase in anaphylaxis admissions since 2002. Venom immunotherapy (VIT) reduces recurrence risk by 95%, with NHS protocols offering 3–5 year regimens using purified vespid or apid extracts.

Our centres employ component-resolved testing (CRD) to differentiate true venom allergies (e.g., Api m 1) from cross-reactive carbohydrate determinants (CCDs), improving diagnostic accuracy by 40%. while recieiving VIT, 90% of patients resume outdoor activities without anxiety, supported by personalised adrenaline auto-injector training.

Large local reactions to insect stings, characterised by swelling exceeding 10 cm and lasting more than 24 hours, occur in up to 26% of adults and are typically non-life-threatening.

Allergy testing and Immunotherapy is generally not indicated for isolated local reactions unless accompanied by systemic symptoms.

Emerging data link mast cell clonal disorders to refractory cases, prompting routine tryptase testing in our severe reaction pathway.

Eczema

Eczema affects 15–20% of UK children, with 30% developing IgE-mediated food allergies due to impaired skin barrier function. The dual allergen exposure hypothesis explains how epidermal breaches allow allergens like peanut proteins to sensitise infants, increasing food allergy risk by 50% in moderate-to-severe cases.

Proactive strategies include lipid-rich emollients (applied twice daily), reducing food allergy incidence by 25%, and maternal Lactobacillus rhamnosus supplementation, which halves eczema onset in high-risk infants. Early allergenic food introduction (e.g., peanut at 4–6 months) is endorsed by BSACI guidelines, with 80% tolerance rates observed in clinical trials. It is possible to do genetic testing for filaggrin mutations (linked to 40% of persistent eczema) and access to biologics like interleukin-13 antagonist, which improves symptoms in 60% of refractory cases. For evidence-based protocols, consult curated GREAT database portal, updated with global trial data monthly.

Eczema in Babies and Food Allergies:  Comprehensive Guide Medical Insights on Evidence-Based Management 

Urticaria

Chronic spontaneous urticaria (CSU) affects 1.8% of the UK population, with 40–50% of paediatric cases linked to autoimmune thyroid dysfunction or occult infections. Triggers like SARS-CoV-2 prolong symptoms in 20% of patients, necessitating D-dimer and CRP screening in refractory cases.

First-line fourfold antihistamine dosing achieves control in 65% of cases, while anti-IgE induces remission in 60% of non-responders within 6 months. Our clinics utilise basophil activation histamine release tests and component allergy tests to exclude food allergies, reducing unnecessary dietary exclusions by 70%.

For physical urticarias, cold tolerance induction in conjunction with medical treatment show 50% efficacy. We also offer autoantibody testing to identify autoimmune subtypes.

Drug allergy and mast cell conditions

Over 90% of suspected penicillin allergies are disproven via graded drug challenges, yet erroneous labels persist, contributing to antibiotic resistance. Use of delabelling programme achieves 96% clearance rates using skin testing and oral provocation, aligned with 2025 GA2LEN guidelines.

For high-risk drugs like NSAIDs, COX-2 selectivity testing identifies safe alternatives in 80% of cases. We offer electronic health records ensuring accurate data exchange across healthcare providers. Drug allergy testing is available after an initial consultation and will take place during a private hospital admission. This service is self-pay only, as the hospital is unfortunately unable to bill insurance companies directly.

Telemedicine video and telephone appointments

We understand that urgent allergy concerns can’t wait. That’s why our telemedicine consultations provide same-day access to experienced specialists, allowing you to receive personalised advice, fast triage, and early treatment planning — all from the comfort of your home or your office. If needed, we can also arrange testing appointments in clinics or home testing directly following your video consultation.